bioAffinity Technologies, Inc.: Business Overview, Financials & Competitive Analysis
bioAffinity Technologies, Inc. scores 4/10 on the AskCyborg Cyborg Score (Mixed). Early-stage cancer diagnostics company with exceptional revenue growth but limited cash runway and path to profitability remains uncertain. CyPath® Lung testing revenue achieved an 86% increase in Q3 2025 demonstrating strong commercial traction and market adoption. However, capital constraints remain a concern with analysts maintaining a Hold rating due.
What is bioAffinity Technologies, Inc.'s industry? bioAffinity Technologies, Inc. (bioaffinitytech.com) operates in Biotechnology/Diagnostics - Oncology. AskCyborg classifies bioAffinity Technologies, Inc. under Biotechnology/Diagnostics - Oncology in its company registry.
bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment through its flagship product CyPath® Lung, which accurately diagnoses early-stage lung can...
Cyborg Score thesis
Early-stage cancer diagnostics company with exceptional revenue growth but limited cash runway and path to profitability remains...
Read the full analyst-debate transcript →Get the Latest bioAffinity Technologies, Inc. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreebioAffinity Technologies, Inc. Overview
Pro stress-test →bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment through its flagship product CyPath® Lung, which accurately diagnoses early-stage lung cancer by analyzing the lung microenvironment to characterize cell populations indicative of lung cancer. Revenue grew approximately 270% to $9.4 million in 2024, a significant increase from $2.5 million in 2023.
Strategic Profile
Pro stress-test →The company operates through two segments: Diagnostic Research and Development and Laboratory Services, offering CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum to find characteristics indicative of lung cancer. CyPath® Lung orders grew by approximately 1,400% over full-year 2023, and the test received Medicare and private insurance reimbursement following CMS addition of a unique CPT code effective January 1, 2024.
Competitive Landscape
Pro stress-test →bioAffinity competes in the lung cancer diagnostics space with players like Biodesix (market cap ~$57M) and other diagnostic research companies. The company's key competitive advantage is CyPath® Lung's ability to dramatically increase overall diagnostic accuracy for lung cancer, with high sensitivity and high specificity in detecting early-stage lung cancer, sold as a laboratory developed test by Precision Pathology Laboratory Services.
Industry Context
bioAffinity Technologies, Inc. operates in Biotechnology/Diagnostics - Oncology.
Key facts
Founded: 2014 · Headquarters: San Antonio, Texas · Revenue: $9.4M (2024) · Market cap: $5.5M